Skip to main content

Development of a novel FGL therapy and translational tests for regenerative treatment of neurological disorders

NEUROFGL

Start Date
End Date
Total Funding
€ 7 807 910
Funding Programme
European Countries Involved

Neurodegenerative disorders such as, Alzheimer’s disease (AD), Mild Cognitive Impairment (MCI), stroke, Traumatic Brain Injury (TBI) and chronic stress create a major economic burden to society and a substantial reduction in quality of life for patients and families. The development of neuroregenerative therapies is notoriously difficult and requires significant investment.

NeuroFGL will contribute to decrease these barriers through:

(1) the clinical advancement of a promising novel regenerative therapy (FGLs) for neurological disorders,

(2) hedging the clinical development by developing tests that enable early clinical assessments to be made, thereby maximising the chance that FGL and other neurogenerative therapies actually become developed to the benefit of patients and society; and

(3) Selecting a target patient population with less variability and thereby easier to study – reducing and time resources needed, and increase predictability .

FGLs is a promising and novel regenerative therapy being the clinical lead development candidate selected from a group of allosteric FGF-receptor modulators (referred to as FGL) mimicking NCAM. FGL has demonstrated positive effects in a number of in vivo models of neurodegeneration, e.g. beta-amyloid induced toxicity, global ischemia and chronic stress. The in vivo effects of FGL suggest a disease-modifying activity in several neurodegenerative disorders, such as neurogenesis.

A phase I clinical study has demonstrated a FGL peptide to be well tolerated and safe. NeuroFGL will refine existing and develop new tests and techniques, that will at an early stage of the clinical development: (1) provide better information on the mechanisms of action (NCAM mimicking allosteric FGF recoter modulation) in man, (2) deliver translational effects seen between animal and man, (3) provide results earlier and cheaper, increasing the iteratiation and (4) select patients with conditions associated with less variability, e.g. patients with AD with a specific EEG or patients progressing to AD identified in patients with MCI. These developments will together provide a more robust basis for the development of FGLs, other drugs with a similar mechanism of action and other therapies for neurodegenerative disorders.

Project partners

Klinikum Der Universitaet Zu Koeln
Forenap Pharma
Psychiatricke Centrum Praha
Enkam Pharmaceuticals A/S
Qualissima
H. Lundbeck As
Kobenhavns Universitet

 
Acknowledgement
Alzheimer Europe's database on research projects was developed as part of the 2020 Work Plan which received funding under an operating grant from the European Union’s Health Programme (2014–2020).